- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01161095
A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The control arm of our study will be women who are randomized to receive LNG-IUS in the Interval time period. The study arm will consist of women randomized to receiving Immediate placement.
The investigators hypothesize that Immediate placement of IUD in the postpartum period will result in a 20% decrease in continuation rates at six months compared to Interval placement.
Secondary outcome measures that we will obtain include:
- Pain at the time of placement
- Postpartum Depression
- Breastfeeding status
- Postpartum weight retention
- Expulsion Rates
- Bleeding Profile
- Uterine Infection(Endometritis)
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Aún no reclutando
- University of Arkansas for the Medical Sciences
-
Contacto:
- Everett F Magann, MD
- Número de teléfono: 501-686-8345
- Correo electrónico: efmagann@uams.edu
-
-
Virginia
-
Portsmouth, Virginia, Estados Unidos, 23507
- Reclutamiento
- Naval Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- All women >37 weeks gestation who desire LNG-IUS for postpartum contraception who do not have a contraindication as described below will be offered participation in our study.
Exclusion Criteria:
Contraindications to the LNG-IUS include:
- Pregnancy or suspicion of pregnancy
- Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
- Postpartum endometritis within the past 3 months
- Known or suspected uterine or cervical neoplasia or unresolved, abnormal pap smear
- untreated acute cervicitis or vaginitis including bacterial vaginosis or other lower genital tract infections
- acute liver disease or liver tumor
- hypersensitivity to any component of the product
- known or suspected carcinoma of the breast
Any of these conditions would exclude the patient from receiving these forms of contraception in our study.
In addition the following intrapartum findings, the following would exclude the patient:
- Delivery <37 weeks
- Intrapartum chorioamnionitis (defined as maternal fever >100.4 and two of the following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid
- Postpartum Hemorrhage (defined as >500cc EBL for spontaneous vaginal delivery or >1000cc for cesarean delivery)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Immediate
LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
|
Mirena (Bayer)- Levonorgestrel-Intrauterine System
|
Comparador activo: Interval
LNG-IUS insertion after 6 weeks postpartum
|
Mirena (Bayer)- Levonorgestrel-Intrauterine System
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Continuation Rates
Periodo de tiempo: 6 months
|
Primary objective: Determine if there is a difference in continuation rates at six months postpartum in women who have the Levonorgestrel Intrauterine System (LNG-IUS) inserted at two time periods: Immediate (after delivery of placenta to 72 hours postpartum) or Interval (after 6 weeks postpartum). Our analysis will be conducted on all randomized women on an intention to treat basis. Once insertion has occurred, evaluation at 6 months postpartum with the presence or absence of the LNG-IUS in the uterus will be determined to calculate the continuation rate. |
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Pain at insertion
Periodo de tiempo: 1 minute
|
Pain will be measured using the validated Visual Analog Scale (VAS) at the time of insertion.
|
1 minute
|
Postpartum Depression
Periodo de tiempo: 6 months
|
Depression history will be determined from the initial data collection sheet upon entry into the study.
The Edinburgh Postnatal Depression Scale will be filled out by the participant at their six week postpartum appointment (routine), and also at six months.
|
6 months
|
Breastfeeding Status
Periodo de tiempo: 6 months
|
We will identify those who plan on breastfeeding their infants prior to discharge from the hospital.
We will also determine the number of hours to Lactogenesis II (avg 40-50 hrs) via phone interview within one week from discharge.
We will determine discontinuation rates and days to discontinuation of breastfeeding at six weeks and six months.
We will also record infant weights at the postpartum appointment and at six months.
|
6 months
|
Postpartum weight retention
Periodo de tiempo: 6 months
|
We will determine each participant's pre pregnancy BMI, BMI at admission to labor and delivery, and BMI at the postpartum appointment and at 6 months.
|
6 months
|
Sexual Function
Periodo de tiempo: 6 months
|
We will determine the number of days from delivery to resumption of sexual intercourse.
We will also have the participant complete the Female Sexual Function Index questionnaire (FSFI) at the postpartum appointment and at 6 months.
|
6 months
|
Expulsion Rate
Periodo de tiempo: 6 months
|
Expulsion rate as well as resumption of contraception (whether LNG-IUS is replaced or another form of contraception is initiated) occurs at the postpartum appointment and at six months
|
6 months
|
Bleeding Profile
Periodo de tiempo: 6 months
|
Each Participant will be asked to complete a monthly menstrual flow calendar to document light, medium, or heavy bleeding.
These will be collected at the postpartum appointment and at six months.
|
6 months
|
Infectious morbidity
Periodo de tiempo: 6 months
|
Postpartum endometritis and pelvic inflammatory disease will be tracked with record review and direct participant questioning at their postpartum appointment and at six months
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- NMCP.2010.0074
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre LNG-IUS
-
University of Texas Southwestern Medical CenterRetiradoAdenomiosis | Sangrado uterino anormal
-
King Chulalongkorn Memorial HospitalTerminado
-
University of HelsinkiUniversity of Turku; Tampere University; University of Eastern Finland; University...Terminado
-
Azienda Ospedaliera di PadovaTerminadoCirrosis hepática | Lesión renal aguda | Síndrome HepatorrenalEstados Unidos, Países Bajos, Corea, república de, Argentina, España, Egipto, Polonia, Alemania, India, Chile, Etiopía, México, Federación Rusa, Brasil, Porcelana, Dinamarca, Francia, Hungría, Italia, Paraguay, Perú
-
Beni-Suef UniversityAún no reclutandoComplicación del dispositivo anticonceptivo intrauterinoEgipto
-
University of North Carolina, Chapel HillTerminadoEmbarazo no planificadoEstados Unidos
-
University of ChicagoTerminado
-
University of Campinas, BrazilTerminadoUso de anticonceptivos | Sangrado debido a un dispositivo anticonceptivo intrauterinoBrasil